home / stock / rdhl / rdhl quote
Last: | $0.451 |
---|---|
Change Percent: | -1.32% |
Open: | $0.437 |
Close: | $0.451 |
High: | $0.4634 |
Low: | $0.437 |
Volume: | 221,058 |
Last Trade Date Time: | 05/01/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.451 | $0.437 | $0.451 | $0.4634 | $0.437 | 221,058 | 05-01-2024 |
$0.4313 | $0.434 | $0.4313 | $0.4378 | $0.4309 | 117,192 | 04-30-2024 |
$0.433 | $0.43 | $0.433 | $0.4401 | $0.42 | 381,285 | 04-29-2024 |
$0.428 | $0.426 | $0.428 | $0.4339 | $0.422101 | 220,476 | 04-26-2024 |
$0.416243 | $0.42 | $0.416243 | $0.4207 | $0.4022 | 272,698 | 04-25-2024 |
$0.4199 | $0.4004 | $0.4199 | $0.438779 | $0.4 | 190,389 | 04-24-2024 |
$0.427786 | $0.4401 | $0.427786 | $0.4477 | $0.3954 | 471,776 | 04-23-2024 |
$0.4424 | $0.44 | $0.4424 | $0.45 | $0.4312 | 84,911 | 04-22-2024 |
$0.452 | $0.42 | $0.452 | $0.455 | $0.401 | 334,831 | 04-19-2024 |
$0.4208 | $0.405 | $0.4208 | $0.437899 | $0.39 | 663,900 | 04-18-2024 |
$0.3855 | $0.39 | $0.3855 | $0.41 | $0.3849 | 240,920 | 04-17-2024 |
$0.385 | $0.38 | $0.385 | $0.3999 | $0.3 | 983,957 | 04-16-2024 |
$0.4042 | $0.432 | $0.4042 | $0.4365 | $0.4032 | 367,811 | 04-15-2024 |
$0.4254 | $0.45 | $0.4254 | $0.4599 | $0.42 | 544,916 | 04-12-2024 |
$0.4541 | $0.4931 | $0.4541 | $0.4948 | $0.4515 | 540,492 | 04-11-2024 |
$0.4815 | $0.511 | $0.4815 | $0.5149 | $0.475 | 403,083 | 04-10-2024 |
$0.498 | $0.52 | $0.498 | $0.5249 | $0.4763 | 324,388 | 04-09-2024 |
$0.524 | $0.532 | $0.524 | $0.5349 | $0.52 | 216,247 | 04-08-2024 |
$0.529 | $0.54 | $0.529 | $0.54 | $0.5211 | 161,829 | 04-05-2024 |
$0.5419 | $0.53 | $0.5419 | $0.55 | $0.52 | 282,255 | 04-04-2024 |
News, Short Squeeze, Breakout and More Instantly...
Redhill Biopharma Ltd. Company Name:
RDHL Stock Symbol:
NASDAQ Market:
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study PR Newswire First patient enrolled in the global, 300-patient, Phase 2 adaptive platform trial arm of RHB-107 (upamostat) 1 for early COVID-19 outpatient treatment, funded through non-...
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights PR Newswire RedHill continues corporate transformation to focus on U.S. government-funded pipeline development in underserved, sizeable therapeutic areas with a disciplined cost-base ...
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price PR Newswire TEL AVIV, Israel and RALEIGH, N.C. , April 2, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialt...